CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $227 | -71.1% | 5 | -64.3% | 0.00% | – |
| Q2 2023 | $786 | -53.0% | 14 | -62.2% | 0.00% | – |
| Q1 2023 | $1,674 | +24.8% | 37 | +12.1% | 0.00% | – |
| Q4 2022 | $1,341 | +34.1% | 33 | +94.1% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 17 | -54.1% | 0.00% | – |
| Q2 2022 | $2,000 | -33.3% | 37 | -32.7% | 0.00% | – |
| Q1 2022 | $3,000 | +50.0% | 55 | +175.0% | 0.00% | – |
| Q4 2021 | $2,000 | -50.0% | 20 | -31.0% | 0.00% | -100.0% |
| Q1 2021 | $4,000 | -50.0% | 29 | -42.0% | 0.00% | -50.0% |
| Q4 2020 | $8,000 | +700.0% | 50 | +400.0% | 0.00% | – |
| Q3 2020 | $1,000 | -50.0% | 10 | -81.8% | 0.00% | -100.0% |
| Q3 2019 | $2,000 | 0.0% | 55 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $2,000 | +100.0% | 55 | 0.0% | 0.00% | – |
| Q1 2019 | $1,000 | 0.0% | 55 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |